Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1998-04-09
2000-09-12
Lambkin, Deborah C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
564317, A61K 31135, C07C21300
Patent
active
061179116
ABSTRACT:
The invention provides a method of treating a mammal having, or at risk of, an indication associated with a TGF-beta deficiency comprising administering one or more agents that is effective to elevate the level of TGF-beta. The invention also provides novel compounds that elevate TGF-beta levels, as well as pharmaceutical compositions comprising compounds that elevate TGF-beta levels, and methods for detecting diseases associated with endothelial cell activation.
REFERENCES:
patent: 3634517 (1972-01-01), Palopoli et al.
patent: 4133814 (1979-01-01), Jones et al.
patent: 4230862 (1980-10-01), Suarez et al.
patent: 4239778 (1980-12-01), Venton et al.
patent: 4307111 (1981-12-01), Crawley
patent: 4310523 (1982-01-01), Neumann
patent: 4323707 (1982-04-01), Suarez et al.
patent: 4380635 (1983-04-01), Peters
patent: 4382143 (1983-05-01), Shepherd
patent: 4418068 (1983-11-01), Jones
patent: 4442119 (1984-04-01), Magarian et al.
patent: 4696949 (1987-09-01), Toivola et al.
patent: 4839155 (1989-06-01), McCague
patent: 4879315 (1989-11-01), Magarian et al.
patent: 4973755 (1990-11-01), Grafe et al.
patent: 4990538 (1991-02-01), Harris et al.
patent: 4996225 (1991-02-01), Toivola et al.
patent: 5015666 (1991-05-01), Magarian et al.
patent: 5047431 (1991-09-01), Schickaneder et al.
patent: 5075321 (1991-12-01), Schreiber
patent: 5098903 (1992-03-01), Magarian et al.
patent: 5189212 (1993-02-01), Ruenitz
patent: 5192525 (1993-03-01), Yang et al.
patent: 5219548 (1993-06-01), Yang et al.
patent: 5254594 (1993-10-01), Niikura et al.
patent: 5280040 (1994-01-01), Labroo et al.
patent: 5389670 (1995-02-01), Fontana
patent: 5391557 (1995-02-01), Cullinan et al.
patent: 5393763 (1995-02-01), Black et al.
patent: 5393785 (1995-02-01), Labrie et al.
patent: 5395842 (1995-03-01), Labrie et al.
patent: 5401730 (1995-03-01), Sauvage et al.
patent: 5411988 (1995-05-01), Bockow et al.
patent: 5418252 (1995-05-01), Williams
patent: 5434166 (1995-07-01), Glasebrook
patent: 5436243 (1995-07-01), Sachs et al.
patent: 5439923 (1995-08-01), Cullinan
patent: 5439931 (1995-08-01), Sales
patent: 5441964 (1995-08-01), Bryant et al.
patent: 5441966 (1995-08-01), Dodge
patent: 5441986 (1995-08-01), Thompson
patent: 5445941 (1995-08-01), Yang
patent: 5446053 (1995-08-01), Keohane
patent: 5446070 (1995-08-01), Mantelle
patent: 5447941 (1995-09-01), Zuckerman
patent: 5451589 (1995-09-01), Dodge
patent: 5451590 (1995-09-01), Dodge
patent: 5451603 (1995-09-01), Piggott
patent: 5455275 (1995-10-01), Fontana
patent: 5457116 (1995-10-01), Black et al.
patent: 5457117 (1995-10-01), Black et al.
patent: 5461064 (1995-10-01), Cullinan
patent: 5461065 (1995-10-01), Black et al.
patent: 5462949 (1995-10-01), Jones et al.
patent: 5462950 (1995-10-01), Fontana
patent: 5466810 (1995-11-01), Godfrey
patent: 5480888 (1996-01-01), Kodama et al.
patent: 5480903 (1996-01-01), Piggott
patent: 5480904 (1996-01-01), Bryant et al.
patent: 5482949 (1996-01-01), Black et al.
patent: 5482950 (1996-01-01), Bryant et al.
patent: 5484797 (1996-01-01), Bryant et al.
patent: 5484808 (1996-01-01), Grinnell
patent: 5489587 (1996-02-01), Fontana
patent: 5491159 (1996-02-01), Malamas
patent: 5491173 (1996-02-01), Toivola et al.
patent: 5492927 (1996-02-01), Gitter et al.
patent: 5496828 (1996-03-01), Cullinan
patent: 5496851 (1996-03-01), Grinnell
patent: 5510370 (1996-04-01), Hock
patent: 5521198 (1996-05-01), Zuckerman
patent: 5534527 (1996-07-01), Black et al.
patent: 5552415 (1996-09-01), May
patent: 5563054 (1996-10-01), Briggs et al.
patent: 5571808 (1996-11-01), Leeds
patent: 5605700 (1997-02-01), DeGregorio et al.
patent: 5652259 (1997-07-01), May
patent: 5658927 (1997-08-01), Magarian et al.
patent: 5658951 (1997-08-01), Magarian et al.
patent: 5686476 (1997-11-01), May
patent: 5733925 (1998-03-01), Kunz et al.
patent: 5770609 (1998-06-01), Grainger et al.
patent: 5847007 (1998-12-01), Grainger et al.
"Schering/Orion Fareston Anti-Estrogen for Treatment of Metastatic Breast Cancer `Similar` to Taxoxifen, FDA Oncologic Committee Says in Approval Vote", F-D-C Reports, 15-16 (Oct. 23, 1995).
Agarwal, A.K., et al., "Estrogen Receptor-Binding Affinity of Tamoxifen Analogs with Various Side Chains and Their Biologic Profile in Immature Rat Uterus", Steroids, 56, 486-489 (Sep. 1991).
Burton, T.M., "Lilly Osteoporosis Treatment Shows Promise", The Wall Street Journal, p. A3, A6 (Jun. 6, 1997).
Butta, A., et al., "Induction of Transforming Growth Factor .beta..sub.1 in Human Breast Cancer in Vivo Following Tamoxifen Treatment", Cancer Research, 52, 4261-4164 (Aug. 1, 1992).
Chandler, et al., "Pyrrolidino-4-iodotamoxifen and 4-Iodotamoxifen, New Analogues of the Antiestrogen Tamoxifen for the Treatment of Breast Cancer", Cancer Research, 51, 5851-5858 (Nov. 1, 1991).
Chandraesekar, B., et al., "Dietary Omega-3 Lipids Delay the Onset and Progression of Autoimmune Lupus Nephritis by Inhibiting Transforming Growth Factor .beta. mRNA and Protein Expression", Journal of Autoimunity, 8, 381-393 (1995).
Colletta, A.A., et al., "Anti-Oestrogens Induce the Secretion of Active Transforming Growth Factor Beta from Human Fetal Fibroblasts", Br. J. Cancer, 62, 405-409 (1990).
Coombes, R.C., et al., "Idoxifene: Report of a Phase I Study in Patients with Metastic Breast Cancer", Cancer Research, 55, 1070-1074 (Mar. 1, 1995).
Cunningham, A., et al., "A Study of the Structural Basis of the Carcinogenicity of Tamoxifen, Toremifene and their Metabolites", Mutation Research, 349, 85-94 (1996).
Davies, A.M., et al., "Peroxidase Activation of Tamoxifen and Toremifene Resulting in DNA Damage and Covalently Bound Protein Adducts", Carcinogenesis, 16, 539-545 (1995).
Dowsett, M., "New Developments in the Hormonal Treatment of Breast Cancer", In: The Treatment of Cancer: Beyond Chemotherapy, Conference Documentation, The Gloucester Hotel, London, 7 p. (Mar. 13-14, 1995).
Dragan, Y.P., et al., "Comparison of the Effects of Tamoxifen and Toremifene on Liver and Kidney Tumor Promotion in Female Rats", Carcinogenesis, 16, 2733-2741 (1995).
Grainger, et al., "The Serum Concentration of Active Transforming Growth Factor (beta) is Severly Depressed in Advanced Atherosclerosis", Nature Medicine, 1, 74-80 (Jan. 1995).
Hardcastle, I.R., et al., "Homologs of Idoxifene: Variation of Estrogen Receptor Binding and Calmodulin Antagonism with Chain Length", J. Med. Chem., 39, 999-1004 (1996).
Hayes, D.F., et al., "Randomized Comparison of Tamoxifen and Two Separate Doses of Toremifene in Postmenopausal Patients with Metastatic Breast Cancer", Journal of Clinical Oncology, 13, 2556-2566 (Oct. 1995).
Jones, R.H.V., et al., "Increased Susceptibility to Metal Catalysed Oxidation of Diabetic Lens .beta..sub.L Crystallin: Possible Protection by Dietary Supplementation with Acetylsalicylic Acid", Exp. Eye Res., 57, 783-790 (1993).
Kellen, J.A., et al., "The Effect of Toremifene on the Expression of Genes in a Rat Mammary Adenocarcinoma", In Vivo, 10, 511-514 (1996).
Knabbe, C., et al., "Induction of Transforming Growth Factor .beta. by the Antiestrogens Droloxifene, Tamoxifen, and Toreifene in MCF-7 Cells", Am. J. Clin. Oncol. (CCT), 14, S15-S20 (1991).
Kopp, A., et al., "Transforming Growth Factor .beta.2 (TGF-.beta.2) Levels in Plasma of Patients with Metastatic Breast Cancer Treated with Tamoxifen", Cancer Research, 55, 4512-4515 (Oct. 15, 1995).
Kuramochi, H., "Conformational Studies and Electronic Structures of Tamoxifen and Toremifene and Their Allylic Carbocations Proposed as Reactive Intermediates Leading to DNA Adduct Formation", J. Med. Chem., 39, 2877-2886 (1996).
Loser, R., et al., "In Vivo and in Vitro Antiestrogenic Action of 3-Hydroxytamoxifen, Tamoxifen and 4-Hydroxytamoxifen", Eur. J. Cancer Clin. Oncol., 21, 985-990 (1985).
Magarian, R.A., et al., "Medicinal Chemistry of Nonsteroidal Antiestrogens: A Review", Current Medicinal Chemistry, 1, 61-104 (1994).
McCague, R., et al., "An Efficient, Large-Scale Synthesis of Idoxifene {(E)-1-[4 -[2-(N-pyrrolidino)ethoxy]phenyl]-1-(4-iodophenyl)-2-phenyl-1-butene}", Organic Preparations and Procedures Int., 26, 343-346 (1994).
McCague, R.,
Grainger David J.
Kasina Sudhakar
Metcalfe James C.
Lambkin Deborah C.
NeoRx Corporation
LandOfFree
Compounds and therapies for the prevention of vascular and non-v does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and therapies for the prevention of vascular and non-v, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and therapies for the prevention of vascular and non-v will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-96775